Prostate Cancer

David R. Wise, MD, PhD, discusses the efficacy of pasritamig plus docetaxel in patients with mCRPC.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

David R. Wise, MD, PhD, unpacks the design of a phase 1b trial of pasritamig plus docetaxel in mCRPC.

The phase 3 TALAPRO-3 study evaluating talazoparib plus enzalutamide HRR gene–mutated mCSPC met its primary end point.

Isaac Y. Kim, MD, PhD, MBA, and Anthony V. D'Amico, MD, PhD, discuss radiotherapy, surgery, and emerging strategies in mHSPC.

Lutetium-177 rosopatamab tetraxetan plus SOC therapies was safe and tolerable in patients with PSMA-positive mCRPC.

Neha Vapiwala, MD, FACR, FASTRO, FASCO, unpacks notable updates from ASCO GU and discusses a trend toward individualized therapy in prostate cancer.

The EC approved an indication extension for niraparib and abiraterone acetate dual-action tablets plus prednisone/prednisolone with ADT in BRCA1/2-mutated mHSPC.

The FDA approved a teclistamab combination in relapsed/refractory myeloma, Pylarify TruVu for PSMA-PET imaging in prostate cancer, and more.

The FDA has cleared Pylarify TruVu injection, a new formulation of its F 18 PSMA imaging agent for prostate cancer.

OncLive spoke with experts in the field of GU oncology to gain perspective on the biggest presentations from the 2026 Genitourinary Cancers Symposium.

The top 5 OncLive TV videos of the week cover insights in lung cancer, renal cell carcinoma, prostate cancer, head and neck cancer, and multiple myeloma.

Ravi A. Madan, MD, discusses data from a phase 2 trial of enzalutamide monotherapy in patients with biochemically recurrent prostate cancer.

Jose Mauricio Mota, MD, PhD, discusses results from the Daro-PET study, which evaluated whether short-course darolutamide increases PSMA expression in prostate cancer.

Adding cabazitaxel to ADT and radiotherapy did not improve PFS or MFS vs SOC after 7 years among patients with high-risk localized prostate cancer.

Lutetium Lu 177 vipivotide tetraxetan–based therapy generated similar QOL outcomes compared with ADT plus an ARPI alone in patients with mHSPC.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

The alpha-emitting radionuclide actinium-225 was well tolerated and produced PSA responses across all dose levels in patients with mCRPC.

Survey results highlight the top RCC and bladder cancer abstracts to watch at the 2026 Genitourinary Cancers Symposium.

Long-term follow-up data from PEACE-3 showed enzalutamide plus radium-223 improved OS and rPFS in patients with mCRPC and bone metastases.

Enrique Gallardo, MD, discusses final OS data from the phase 3 PEACE-3 trial of radium-223 with/without enzalutamide in mCRPC.

Stacy Loeb, MD, discusses findings from a study evaluating microplastics in prostate cancer tissue.

Short-course darolutamide boosted PSMA expression in some high-risk localized prostate cancer, supporting improved PSMA PET imaging strategies.

The addition of capivasertib to abiraterone elicited an rPFS advantage and preserved QOL compared with placebo plus abiraterone in PTEN-deficient mHSPC.

Abiraterone acetate, prednisone, and olaparib combination therapy boosted efficacy outcomes in first-line mCRPC.